Please login to the form below

Not currently logged in
Email:
Password:

Indian court rejects Novartis patent demand

A court in the Indian city of Chennai has rejected a claim by the Swiss pharmaceutical company Novartis regarding its cancer drug, Glivec (imatinib).

A court in the Indian city of Chennai has rejected a claim by the Swiss pharmaceutical company Novartis regarding its cancer drug, Glivec (imatinib).

Novartis was demanding that India grant a patent for Glivec to prevent cheap copies being made. The government in New Delhi opposed the move, saying that granting such a patent would violate India's patent legislation.

Novartis has been seeking a patent for Glivec in India, challenging the Indian patent law which currently does not protect incremental innovation. Indian law does not grant patents for modifications to old medicines, but only to properly innovative drugs developed after 1995.

6th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

A snapshot of… Exscientia
...
Patients are ready for virtual clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Keep your audiences close
How getting up close and personal with target audiences can fuel creativity...

Infographics